Cargando…
BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer
Lung cancer is the leading cause of cancer deaths worldwide. Immunotherapies (IT) have been rapidly approved for lung cancer treatment after the spectacular results in melanoma. Responses to the currently used checkpoint inhibitors are strikingly good especially in metastatic diseases. However, dura...
Autores principales: | Demerlé, Clemence, Gorvel, Laurent, Olive, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438526/ https://www.ncbi.nlm.nih.gov/pubmed/34532285 http://dx.doi.org/10.3389/fonc.2021.682007 |
Ejemplares similares
-
Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors
por: Demerlé, Clémence, et al.
Publicado: (2023) -
BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM
por: Battin, Claire, et al.
Publicado: (2022) -
Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding
por: Spodzieja, Marta, et al.
Publicado: (2020) -
Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses
por: Spodzieja, Marta, et al.
Publicado: (2017) -
Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis
por: Lan, Xiuwen, et al.
Publicado: (2017)